Summary
This European multicentre observational study examined clinical outcomes in patients with advanced urothelial cancer who received sequential anti-PD-1/PD-L1 immunotherapy (frontline followed by second-line). The analysis as suggested by the title) assessed efficacy and safety metrics in this treatment progression pathway, contributing evidence on the role of checkpoint inhibitor sequencing in advanced urothelial malignancy.
UK applicability
Findings are directly applicable to UK oncology practice, as anti-PD-1/PD-L1 agents are standard-of-care options in advanced urothelial cancer across NHS trusts. Results may inform sequencing strategies and patient selection criteria for checkpoint inhibitor therapy in the United Kingdom.
Key measures
Clinical response rates, progression-free survival, overall survival, treatment tolerability across sequential anti-PD-1/PD-L1 regimens
Outcomes reported
The study examined clinical outcomes in patients with advanced urothelial cancer who progressed through sequential anti-PD-1/PD-L1 checkpoint inhibitor therapies (frontline followed by second-line treatment). Measures likely included overall survival, progression-free survival, response rates, and safety profiles across treatment sequences.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.